| Question 1: The 90% beta radiation energy deposition distance in water with Re-186 radionuclide is: |
| Reference: | Simpkin DJ & Mackie TR. EGS4 Monte Carlo determination of the beta dose kernel in water. Med Phys 17: 179-186, 1990. |
| Choice A: | 0.8 mm |
| Choice B: | 1.8 mm |
| Choice C: | 4.4 mm |
| Choice D: | 5.3 mm |
| Question 2: According to NRC Regulatory Guide 8.39, with up to how much administered Re-186 activity, licensees may release the patient, as long as the measured dose rate at 1 meter is no more than 0.15 mSv/h? |
| Reference: | https://www.nrc.gov/docs/ML0833/ML083300045.pdf |
| Choice A: | 33 mCi |
| Choice B: | 150 mCi |
| Choice C: | 430 mCi |
| Choice D: | 770 mCi |
| Question 3: Which answer below is closest to the biological half-life of the antibody Omburtamab in the cerebral spinal fluid (CSF)? |
| Reference: | Pandit-Taskar N, Zanzonico PB, Kramer K, Grkovski M, Fung EK, Shi W, Zhang Z, Lyashchenko SK, Fung AM, Pentlow KS, Carrasquillo JA, Lewis JS, Larson SM, Cheung NV, Humm JL. Biodistribution and Dosimetry of Intraventricularly Administered 124I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. J Nucl Med. 2019 Dec;60(12):1794-1801. PMC6894373. |
| Choice A: | 10 minutes |
| Choice B: | 1 hour |
| Choice C: | 4 hours |
| Choice D: | 10 hours |
| Choice E: | Antibody remains permanently trapped in the CSF |
| Question 4: Which of the below most accurately describes the radionuclide iodine-124 and its suitability for dosimetry? |
| Reference: | Pentlow KS, Graham MC, Lambrecht RM, Daghighian F, Bacharach SL, Bendriem B, Finn RD, Jordan K, Kalaigian H, Karp JS, Robeson WR, Larson SM. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996 Sep;37(9):1557-62. PMID: 8790218. |
| Choice A: | It is a short 4-hour half-life positron emitter that results in a radiation dose to the patient similar to an FDG scan. |
| Choice B: | It does not emit particulate radiation such as beta particles but only gamma rays producing images with a minimal diagnostic radiation dose burden to the patient. |
| Choice C: | The positron emission energies are all very low energy producing highly quantitative images with a minimal diagnostic radiation dose burden to the patient. |
| Choice D: | It is a positron emitter with a long 4-day half-life that results in a comparable radiation dose to the therapeutic isotope 131I per MBq. Yet, it can produce highly quantitative images at low administered activity. |
| Question 5: What is the theoretical advantage of intraarterial peptide receptor radionuclide therapy (PRRT), in comparison to conventional intravenous PRRT administration? |
| Reference: | Kratochwil, Clemens, et al. "Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors." Clinical Cancer Research 16.10 (2010): 2899-2905. |
| Choice A: | Faster whole body clearance |
| Choice B: | Reduced hepatic dose |
| Choice C: | Increased tumor uptake |
| Choice D: | Decreased therapeutic ratio |
| Question 6: What is the most common site of metastasis for neuroendocrine tumors? |
| Reference: | Lawhn-Heath, Courtney, et al. "Intraarterial peptide receptor radionuclide therapy using 90Y-DOTATOC for hepatic metastases of neuroendocrine tumors." Journal of Nuclear Medicine 62.2 (2021): 221-227. |
| Choice A: | Brain |
| Choice B: | Bones |
| Choice C: | Lungs |
| Choice D: | Liver |
